溶血性贫血 中国就医指南

Hemolytic anemia is a heterogeneous group of blood disorders characterized by premature destruction (hemolysis) of red blood cells (RBCs) at a rate exceeding the bone marrow’s capacity to compensate. Unlike anemias caused by reduced production (e.g., aplastic or iron-deficiency anemia), hemolytic anemia stems from increased RBC turnover—either intravascular (within circulation) or extravascular (primarily in the spleen and liver). Pathogenesis falls into two broad categories: intrinsic (hereditary) defects—such as abnormalities in RBC membrane (e.g., hereditary spherocytosis), enzymes (e.g., G6PD deficiency), or hemoglobin (e.g., sickle cell disease)—and extrinsic (acquired) triggers—including autoimmune mechanisms (autoimmune hemolytic anemia, AIHA), infections (e.g., malaria, Mycoplasma pneumoniae), medications (e.g., penicillin, cephalosporins), toxins, mechanical injury (e.g., microangiopathic hemolytic anemia in TTP or HUS), and malignancies (e.g., lymphoproliferative disorders). Epidemiologically, inherited forms vary by geography and ethnicity: G6PD deficiency affects up to 400 million people globally, with high prevalence in Africa, Mediterranean, and Southeast Asia; hereditary spherocytosis occurs in ~1 in 2,000–5,000 individuals in populations of Northern European descent. Acquired AIHA has an incidence of approximately 1–3 per 100,000 person-years, rising sharply after age 50. Risk factors include genetic predisposition, autoimmune comorbidities (e.g., SLE, CLL, lymphoma), recent infection or vaccination, certain drugs, pregnancy, and exposure to oxidative stressors. Clinical manifestations range from asymptomatic to life-threatening: fatigue, pallor, jaundice, dark urine (hemoglobinuria), dyspnea on exertion, tachycardia, splenomegaly, and—in severe or acute cases—acute kidney injury, heart failure, or shock. Chronic hemolysis may lead to pigment gallstones, leg ulcers, and pulmonary hypertension. Quality of life is significantly impacted: patients often experience persistent fatigue, exercise intolerance, anxiety about hemolytic crises, treatment-related side effects (e.g., corticosteroid-induced insomnia or weight gain), and psychosocial burden due to diagnostic uncertainty or recurrent hospitalizations. Children with congenital forms may face developmental delays or school absenteeism; adults report reduced work productivity and social withdrawal. Early diagnosis—via peripheral smear, reticulocyte count, LDH, haptoglobin, bilirubin, direct Coombs test, and flow cytometry—is critical to guide targeted therapy and prevent complications. Multidisciplinary care involving hematologists, transfusion medicine specialists, and supportive services improves long-term outcomes and patient-centered quality of life.

# 溶血性贫血治疗方案与费用明细（血液科）

一、非手术/保守治疗方案

• •糖皮质激素（如泼尼松）：适用于自身免疫性溶血性贫血（AIHA）初治患者；疗程6–12周，起始剂量0.5–1.5 mg/kg/d；药品费：80–300元/月；含血常规、网织红细胞计数、Coombs试验等监测，检查费：420–680元/疗程。
• •免疫抑制剂（环孢素A、霉酚酸酯）：用于激素无效或依赖者；药品费：2,800–6,500元/月；需血药浓度监测+肝肾功能动态评估，检验费：1,200–2,000元/季度。
• •补铁/叶酸支持治疗：仅限合并缺铁或高代偿性增生者；口服制剂费：30–120元/月。

二、手术/介入治疗方案

• •脾切除术（开腹/腹腔镜）：适用于遗传性球形红细胞增多症、难治性AIHA且抗体检出阳性者；手术费+麻醉+住院（7–10天）：32,000–48,000元；术前全套检查（LDH、胆红素、超声、心肺评估等）：2,100–3,500元。

三、特殊复杂方案

• •利妥昔单抗（375 mg/m²×4周）：用于CD20+难治性AIHA；单周期费用：18,000–26,000元（含输注监护及感染预防）；
• •造血干细胞移植：仅限重型遗传性溶血（如PK缺乏症伴反复危象）且有HLA相合供者；全流程费用：350,000–520,000元（含预处理、移植、ICU支持及GVHD防治）。

方案快速选择指南

• •预算有限/初发轻症：首选激素+定期随访（总费用≤2,000元/3个月）；
• •中重度/激素依赖：免疫抑制剂联合监测（年均支出约4–8万元）；
• •遗传性明确+反复溶血危象：腹腔镜脾切除为性价比最优根治路径（单次投入≤5万元）；
• •移植适应证患者：建议至国家级血液病中心评估，纳入医保特药及大病救助通道。